SEC Comment Letter 0000000000-23-005199 to Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: May 16, 2023 · CIK: 0001645460 · Accession: 0000000000-23-005199
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271786
Letter
United States securities and exchange commission logo May 16, 2023 Daniel R. Passeri Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, MA 02135 Re:Cue Biopharma, Inc. Registration Statement on Form S-3 Filed May 9, 2023 File No. 333-271786 Dear Daniel R. Passeri: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Caroline Dotolo, Esq.
Show Raw Text
United States securities and exchange commission logo
May 16, 2023
Daniel R. Passeri
Chief Executive Officer
Cue Biopharma, Inc.
40 Guest Street
Boston, MA 02135
Re:Cue Biopharma, Inc.
Registration Statement on Form S-3
Filed May 9, 2023
File No. 333-271786
Dear Daniel R. Passeri:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Caroline Dotolo, Esq.